Figure 1: CD3-specific antibody treatment increases systemic TGF-β, which requires the presence of macrophages and iDCs. Figure 2: iDCs produce TGF-β upon ingestion of apoptotic cells and induce Foxp3 ...

Multiple Myeloma (MM) is the second most common hematological malignancy that originates from plasma cells. Over the last 20 years, treatment for patients of MM has advanced significantly; but despite ...

ROYERSFORD, Pa.--(BUSINESS WIRE)--Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled ...

CD3 (including its subunits CD3ε, CD3δ, CD3γ, and CD3ζ) is the central component of the TCR-CD3 complex and is crucial for recognizing T cells and responding to antigens. Every subunit of CD3 has ...

CD19-targeted therapies, including CAR-T therapies and TCEs have demonstrated promising therapeutic potential in the treatment of autoimmune diseases. However, the clinical development of TCEs has ...

Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study. Background: MGD009 is a B7-H3 x CD3 ...